Analysis BioNTech’s May Marathon: Earnings, a Shareholder Vote, and a Rival’s Data Test the Oncology Pivot
For a company sitting on nearly €17 billion in cash, BioNTech is navigating a remarkably precarious moment. The German biotech enters a packed May calendar with a radical restructuring plan,...